Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.60 |
| ▸ | BRD4 | O60885 | 6/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22464461 | 0.98 | CRBN (0.60) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL23772949 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL22464808 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL29137874 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL20362334 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL26321010 | 0.96 | CRBN (0.64) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL16569451 | 0.94 | CRBN (0.62) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL30628170 | 0.94 | CRBN (0.62) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL26321021 | 0.94 | CRBN (0.64) | CRBNBRD4IKZF3TNFIL1B | |
| SCHEMBL22075932 | 0.94 | BRD4 (0.57) | CRBNBRD4DDB1MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-117777223-A | ARE-PROTAC compound and preparation method and application thereof | 中国药科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-111205282-B | ER protein modulators and uses thereof | 上海科技大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-110240629-B | Protein degradation targeting BCR-ABL compound and antitumor application thereof | 上海科技大学 | 2023-10-03 | — | — | CN | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-111205282-A | ER protein modulators and uses thereof | 上海科技大学 | 2020-05-29 | — | — | CN | disclosed |
| US-20140024807-A1 | Lenalidomide and Thalidomide Immunoassays | SALADAX BIOMEDICAL INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440796-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8293492-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-22 | — | — | US | disclosed |
| US-20120064549-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-8114621-B2 | Lenalidomide and thalidomide immunoassays | SALADAX BIOMEDICAL INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| WO-2011112358-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | SALADAX BIOMEDICAL INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885BRD4 504/4885IKZF3 976/4885 |
| US-20130211052-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885BRD4 504/4885IKZF3 976/4885 |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | ESR2, ESRRG, ESRRA | CRBN 18/4885BRD4 1207/4885IKZF3 1264/4885 |
| US-20110223611-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | FCGRT, MALT1, SERPINA6 | CRBN 26/4885BRD4 504/4885IKZF3 976/4885 |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | CRBN, VHL, CBL | CRBN 1/4885BRD4 1105/4885IKZF3 1017/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | CRBN 6/4885BRD4 2132/4885IKZF3 1051/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | CRBN 2656/4885BRD4 245/4885IKZF3 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.